Implantable scaffolds to make CAR‑T therapy stronger and cheaper for brain tumors
Bioinstructive Scaffolds for Potent and Affordable CAR-T Cell Therapy Against Brain Tumors
This project aims to use a biocompatible implant placed at the tumor site to help CAR‑T immune cells reach and kill glioblastoma cells while reducing the need for repeated, costly infusions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11294220 on NIH RePORTER |
What this research studies
From a patient's perspective, researchers are designing a safe, bioinstructive scaffold that can be placed into the tumor cavity during surgery to hold and support CAR‑T cells locally. The scaffold is intended to help CAR‑T cells cross barriers in the brain, resist local immunosuppression, and stay active longer so fewer doses are needed. The team will test different scaffold materials and CAR‑T combinations in the lab and in preclinical models to find the safest and most effective approach. If those results are promising, the work would move toward clinical testing at specialized medical centers.
Who could benefit from this research
Good fit: Ideal candidates would be people with glioblastoma who are undergoing tumor resection and could receive local delivery of CAR‑T cells into the resection cavity or ventricular system.
Not a fit: People with non-brain cancers, those who cannot safely undergo neurosurgery or catheter placement, or those with medical conditions preventing immunotherapy are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, this could make CAR‑T treatment more effective against glioblastoma and more accessible by lowering costs and reducing repeat hospital procedures.
How similar studies have performed: CAR‑T therapy has been highly successful for some blood cancers and early CAR‑T trials in glioblastoma have shown promise, but using implantable scaffolds to sustain CAR‑T locally is a newer strategy with limited human data.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Brudno, Yevgeny — Univ of North Carolina Chapel Hill
- Study coordinator: Brudno, Yevgeny
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.